Aurinia Pharmaceuticals' IFRS loss for 3 months of 2022 was $37.63 million, down 25.3% from $50.379 million in the previous year. Revenue increased 23.7 times to $21.625 million compared to $0.914 million a year earlier.
Aurinia Pharmaceuticals' IFRS loss for 3 months of 2022 was $37.63 million, down 25.3% from $50.379 million in the previous year. Revenue increased 23.7 times to $21.625 million compared to $0.914 million a year earlier. 
ir.auriniapharma.com
English (US) 